Psoriasis: The Evidence-Based Supplement Protocol

← Back to articles

Psoriasis is an immune-mediated inflammatory skin disease driven by IL-17/IL-23 pathway activation. The interventions with the strongest evidence are all medical: topical corticosteroids, topical vitamin D analogues (calcipotriol), phototherapy, methotrexate, and the biologics targeting TNF-α, IL-17 and IL-23. No oral supplement comes close to these in effect size. The honest summary of the supplement literature is that the evidence is weak and inconsistent — most positive signals appear only when a supplement is added on top of conventional therapy, and several widely sold products have null data. This page grades what is actually known, strongest evidence first, and is explicit about where the data does not support the marketing.

Topical vitamin D analogues — strong; oral vitamin D — weak

It is important to separate two different things. Topical vitamin D analogues (calcipotriol/calcipotriene, calcitriol) are genuinely first-line topical therapy with robust evidence and are prescribed routinely — but these are drugs applied to the skin, not the oral vitamin D supplement most readers have in mind. The case for oral vitamin D is much thinner. A 2020 systematic review and meta-analysis of randomized trials found that oral vitamin D produced only a small reduction in PASI at six months that lost statistical significance after appropriate adjustment, and the authors concluded a favorable effect "could not be verified" (PMID 33183899). A separate 12-month placebo-controlled RCT (100,000 IU/month) found no difference in PASI between groups, though 25-OH-D rose in both arms (PMID 29480035). Evidence grade: weak/insufficient for oral supplementation. Reasonable use is repletion of documented deficiency (a target of roughly 30 ng/mL, capped at standard safe doses) rather than expecting skin clearance from a pill.

Omega-3 (EPA/DHA) — weak as monotherapy, possible adjunct benefit

This is the supplement most overstated in popular psoriasis advice. The best synthesis — an 18-RCT systematic review (927 participants) — found that omega-3 monotherapy had no effect on PASI, lesion area or pruritus, and that a meaningful PASI reduction (mean difference about -3.9) appeared only when fish oil was combined with conventional treatment (PMID 31995220). A second meta-analysis of 13 RCTs concluded bluntly that "the current evidence does not support the use of fish oil supplement in treating psoriasis" (PMID 31805911). Evidence grade: weak. If used at all, omega-3 (around 2–3 g EPA+DHA daily) is reasonable mainly for cardiometabolic comorbidity reduction in psoriasis patients, not as a skin treatment. Cautions: high doses can mildly increase bleeding risk and may interact with anticoagulants.

Bioavailable curcumin — limited but the most encouraging adjunct signal

A small randomized, double-blind, placebo-controlled trial added a lecithin-delivery curcumin (Meriva, ~2 g/day) to topical steroids in mild-to-moderate plaque psoriasis and found a greater PASI reduction and a significant fall in serum IL-22 versus topical steroids alone over 12 weeks (PMID 26090395). This is a single, small, industry-relevant trial, so the finding is promising but not definitive. Evidence grade: limited. Plain turmeric powder is poorly absorbed; only bioavailable curcumin formulations have been tested. Curcumin can theoretically add to antiplatelet effects and may cause mild GI upset.

Selenium — repletion only, in documented deficiency

Older observational data found lower whole-blood and plasma selenium in moderate-to-severe psoriasis, but interventional evidence that supplementation improves the skin is lacking. The Cochrane review of dietary supplements for eczema (a closely related antioxidant question) likewise found no convincing benefit for selenium. Evidence grade: insufficient. If supplementing for genuine deficiency, cap at 200 mcg/day — chronic excess selenium is itself toxic (selenosis: hair loss, nail changes, neuropathy).

What doesn't work / overhyped

Avoid "psoriasis cleanse" and "detox" formulas — there is no mechanism and no evidence. Skip high-dose biotin: it has no psoriasis evidence and, importantly, interferes with many laboratory immunoassays (including thyroid and troponin tests), which can produce dangerously misleading results. Evening primrose oil has null trial data for inflammatory skin disease and should not be relied on. Most fundamentally, do not substitute any supplement for methotrexate, phototherapy or a biologic in moderate-to-severe disease — that trade-off risks uncontrolled inflammation and, in some patients, progression to psoriatic arthritis.

How to think about a protocol

Build on the medical foundation: a topical corticosteroid plus a topical vitamin D analogue and emollients for mild disease, escalating to phototherapy or a biologic for moderate-to-severe disease, under dermatology care. Two lifestyle measures have effect sizes that rival or exceed any supplement and are strongly supported by guidelines: smoking cessation and weight loss, both of which reduce psoriasis severity and cardiometabolic risk (PMID 30772097). If a patient still wants to add a supplement, bioavailable curcumin alongside topical therapy has the most encouraging (if limited) signal; correcting documented vitamin D or selenium deficiency is defensible; omega-3 is best justified for comorbidity rather than skin. Set expectations honestly — none of these will clear plaques on their own. See the condition page and our vitamin D dosing guide.